Is Inovio Stock Set to Rebound?

Inovio Pharmaceuticals (NASDAQ: INO) has been one of the disappointments of the coronavirus vaccine race. Last year, the company fell behind in the development of its vaccine candidate. And this year, the stock has dropped about 18%.

Now, however, it looks like things may be changing for Inovio. U.S. regulators recently gave the company the nod to start its late-stage trial, and this week Inovio laid out its plan to tackle the omicron variant. Does all of this mean Inovio stock is ready to rebound? Let's take a look.

Image source: Getty Images.

Continue reading

Source Fool.com